Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 11/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.60 |
| ▸ | MEN1 | O00255 | 4/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.60 |
| ▸ | MAPT | P10636 | 1/20 | 0.60 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.60 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.60 |
| ▸ | RELA | Q04206 | 1/20 | 0.60 |
| ▸ | NPC1 | O15118 | 9/20 | 0.57 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.56 |
| ▸ | PKM | P14618 | 4/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3794688 | 0.82 | RAB9A (0.62) | RAB9ASMN1; SMN2MEN1KMT2AMAPT | |
| SCHEMBL2175131 | 0.81 | RAB9A (0.60) | RAB9ASMN1; SMN2MEN1KMT2AMAPT | |
| SCHEMBL28089066 | 0.80 | FFAR2 (0.50) | RAB9ASMN1; SMN2MEN1KMT2AMAPT | |
| SCHEMBL6474925 | 0.79 | RAB9A (0.58) | RAB9ASMN1; SMN2MEN1KMT2AMAPT | |
| SCHEMBL26818237 | 0.79 | RAB9A (0.58) | RAB9ASMN1; SMN2MEN1KMT2AMAPT | |
| SCHEMBL6285776 | 0.78 | RAB9A (0.74) | RAB9ASMN1; SMN2MEN1KMT2AMAPT | |
| SCHEMBL15943684 | 0.78 | RAB9A (0.57) | RAB9ASMN1; SMN2MEN1KMT2AMAPT | |
| SCHEMBL3040422 | 0.78 | RAB9A (0.57) | RAB9ASMN1; SMN2MEN1KMT2AMAPT | |
| SCHEMBL6284862 | 0.77 | RAB9A (0.59) | RAB9ASMN1; SMN2MEN1KMT2AMAPT | |
| SCHEMBL6361249 | 0.76 | SMN1; SMN2 (0.61) | RAB9ASMN1; SMN2MEN1KMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100105745-A1 | Suppression of cancer and method for evaluating anticancer agent based on the effect of inhibiting gsk3 beta | NATIONAL UNIVERSITY CORPORATION KANAZAWA UNIVERSITY (JP) | 2010-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105745-A1 | Suppression of cancer and method for evaluating anticancer agent based on the effect of inhibiting gsk3 beta | GSK3B, GSK3A, GSKIP | RAB9A 3465/4885SMN1; SMN2 2592/4885MEN1 3680/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.